Endpoints News
Beeline's promising mid-stage lupus data Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T Wed Th F
9 September, 2026
Build your U.S team - from first hire to field force.
With 30+ commercial builds and 2,500 placements in the past 2 years, Mix Talent delivers medical, sales, access, and reimbursement talent for global biopharma entering the U.S.
sponsored by Mix Talent
top stories
1. From lab banter to a Lasker Award: The science behind narcolepsy
2. Beeline Medicines reports promising mid-stage lupus data
3. NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand
4.
news briefing
Compass posts positive psilocybin data; Solstice makes $225M debut
5. Kura Oncology spins out diabetes pipeline with $50M and Lilly's help
6. Exclusive: Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic
7. Tyra finds ray of sunshine in otherwise cloudy Phase 2 bladder cancer data
8. Evommune's lead drug flunks its second I&I trial this summer
9. Expanding its biopharma plans, Anthropic looks for a life sciences dealmaker
more stories
 
Karen Weintraub
.

This year’s Lasker Awards were announced today and among the three winners were the scientists who revealed the connection between narcolepsy and the peptide orexin. Masashi Yanagisawa and Emmanual Mignot talk with Lei Lei Wu about the quarter-century journey between basic discovery and successful treatment.

.
Karen Weintraub
Deputy Editor, Endpoints News
Lasker Award winners Masashi Yanagisawa and Emmanuel Mignot
1
by Lei Lei Wu

The path to un­der­stand­ing a com­mon sleep dis­or­der start­ed with lab ban­ter and trav­eled through mice, dogs and more re­cent­ly, the flu virus.

Now, the...

Read the full story
2
by Max Bayer

The busi­ness of ad­vanc­ing shelved phar­ma as­sets con­tin­ues to reap ben­e­fits, this time for Bee­line Med­i­cines and a lu­pus can­di­date pro­vid­ed by Bris­tol My­ers Squibb.

The...

Read the full story
3
by Kyle LaHucik

Af­ter tin­ker­ing with the bi­ol­o­gy of the broad­ly ap­peal­ing an­ti-in­flam­ma­to­ry NL­RP3 path­way, NodThera is now plot­ting its piv­otal tri­al plans for 2027.

The decade-old biotech...

Read the full story
News Briefing: Quick hits from the biopharma web
4
by ENDPOINTS

Plus news about Luma, In­no Med­i­cine, Schrödinger, As­sem­bly Bio­sciences, Gilead, Ley­den Labs, Navion, Ridge Bio, and Opus Ge­net­ics. 

📊 Com­pass Path­ways touts one-year da­ta for...

Read the full story
5
by Kyle LaHucik

Ku­ra On­col­o­gy, the mak­er of the menin in­hibitor Komzifti, is spin­ning out its di­a­betes R&D to a new com­pa­ny that has at­tract­ed the at­ten­tion...

Read the full story
ENDPOINTS at #JPM26
One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.